MDG 20XX
Alternative Names: MDG-20XXLatest Information Update: 29 Aug 2023
At a glance
- Originator MediGene AG
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 27 Jun 2023 MDG 20XX is available for licensing as of 27 Jun 2023. https://medigene.com/science/pipeline/
- 27 Jun 2023 Early research in Solid tumours in Germany (Parenteral) ((Medigene pipeline, June 2023)